In 2020, Chen et al. investigated the anticancer effects of dihydroartemisinin on esophageal cancer and found that dihydroartemisinin treatment activated autophagy by inhibiting the Akt/mTOR signaling pathway in two human squamous cell lines (TE-1 and Eca109) [62]. Here, AKT1 is linked to esophageal cancer.